+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nocturia - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • March 2022
  • Region: Global
  • DelveInsight
  • ID: 4037287
The publisher’s, “Nocturia - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Nocturia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Nocturia Understanding

Nocturia: Overview

Nocturia is a condition that causes you to wake up during the night to urinate. This can be thought of as nocturnal urinary frequency - having to urinate more often at night. This condition becomes more common as people age and occurs in both men and women. Nocturia can be caused by: Polyuria: when a body makes too much urine in a 24-hour period, Nocturnal polyuria: when a body makes too much urine during the night, Bladder storage problems: when a bladder doesn't store or release urine well. Mixed nocturia: when more than one of these problems are happening. Nocturia can have significant health consequences. It may be connected to serious underlying problems, and nighttime bathroom trips can both disrupt sleep and create additional health concerns. Anticholinergic medications (these can reduce symptoms of an overactive bladder), Bumetanide (Bumex®), Furosemide (Lasix®) (diuretics that assist in regulating urine production), Desmopressin (DDAVP®) (helps the kidneys produce less urine) might be helpful in treating the condition.

'Nocturia - Pipeline Insight, 2022' report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nocturia pipeline landscape is provided which includes the disease overview and Nocturia treatment guidelines. The assessment part of the report embraces, in depth Nocturia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nocturia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Nocturia R&D. The therapies under development are focused on novel approaches to treat/improve Nocturia.

Nocturia Emerging Drugs Chapters

This segment of the Nocturia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nocturia Emerging Drugs

FE 201836: Ferring Pharmaceuticals

An oral solution of FE 201836 for treatment of Nocturia is being developed by Ferring Pharmaceuticals. A Phase II clinical trial evaluating FE201836 to treat nocturia has been completed.

Further product details are provided in the report

Nocturia: Therapeutic Assessment

This segment of the report provides insights about the different Nocturia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nocturia

There are approx. 3+ key companies which are developing the therapies for Nocturia. The companies which have their Nocturia drug candidates in the most advanced stage, i.e. Phase II include, Ferring Pharmaceuticals.


The publisher’s report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Nocturia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nocturia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nocturia therapeutic drugs key players involved in developing key drugs.

Nocturia Report Insights

  • Nocturia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Nocturia Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Nocturia drugs?
  • How many Nocturia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nocturia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nocturia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nocturia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Table of Contents

IntroductionExecutive Summary
Nocturia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Mid Stage Products (Phase II)
  • Comparative Analysis

FE 201836: Ferring Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Inactive Products
  • Comparative Analysis
  • Nocturia Key Companies
  • Nocturia Key Products
  • Nocturia- Unmet Needs
  • Nocturia- Market Drivers and Barriers
  • Nocturia- Future Perspectives and Conclusion
  • Nocturia Analyst Views
  • Nocturia Key Companies
  • Appendix

List of Tables
Table 1 Total Products for Nocturia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Nocturia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Sanwa Kagaku Kenkyusho
  • Ferring Pharmaceuticals
  • Tacurion Pharma